NEWS! 3 units sold!!!!!
Press Release Source: CDEX, Inc.
Texas Children's Hospital Selects ValiMed(TM) Medication Validation System for Hospital Pharmacy
Tuesday August 15, 11:00 am ET
Three ValiMed Units Purchased to Verify Compounded Medication Doses, and Validate Narcotic Returns
ROCKVILLE, Md.--(BUSINESS WIRE)--Aug. 15, 2006--CDEX Inc. (OTCBB:CEXI - News) announced today that Texas Children's Hospital has purchased three ValiMed systems to perform end product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed Medication Validation System, developed by CDEX and distributed exclusively by Baxa Corporation, provides clinicians with a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded. Texas Children's Hospital is an internationally recognized full-care pediatric hospital located in the Texas Medical Center in Houston. One of the largest pediatric hospitals in the United States, Texas Children's Hospital is dedicated to providing the finest possible pediatric patient care, education, and research.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing to the patient care area. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"The Pharmacy Leadership at Texas Children's Hospital continues to look for opportunities to enhance our safety strategies. Since the majority of our medications are compounded, the ValiMed technology will provide an additional layer of safety and enable us to verify accuracy of multiple doses in a more timely fashion," said Karen Gurwitch, Director of Pharmacy at Texas Children's.
"We feel privileged to add Texas Children's Hospital to our growing list of internationally recognized healthcare organizations that are using ValiMed," said Jim Griffin, President and CEO of CDEX Inc. "Texas Children's recognizes the value of ValiMed and has purchased multiple ValiMed units for use across their hospital pharmacy compounding, medication dispensing, and return verification processes."
ValiMed validates medications to ensure that the correct drugs, in the correct amounts, in the correct diluent have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation (www.baxa.com) of Englewood, Colorado.
About Texas Children's Hospital
Established in 1954 and located in the heart of the Texas Medical Center in Houston, Texas Children's Hospital is committed to providing the finest possible patient care, education and research. The nonprofit hospital is ranked among the top five pediatric hospitals nationwide by both U.S. News and World Report and Child. For more information, visit the website at www.texaschildrenshospital.org.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at www.baxa.com.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
Contact:
CDEX, Inc.
Jerry Blair, 301-881-0080
jblair@cdex-inc.com
Source: CDEX, Inc.
AI
